<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02432365</url>
  </required_header>
  <id_info>
    <org_study_id>AGOG14-001/TGOG1008</org_study_id>
    <secondary_id>IRB103-4781A3</secondary_id>
    <nct_id>NCT02432365</nct_id>
  </id_info>
  <brief_title>Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy</brief_title>
  <official_title>Phase II Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asian Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taiwanese Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose was to establish a quick (7-day) cycle schedule of paclitaxel (60 mg/m2)
      combining with cisplatin (40 mg/m2) NAC regimen could be tolerated without interfering the
      following surgical treatment and a favorable overall survival rate for stages IB2 and IIA2
      cervical squamous cell carcinoma (SCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label, Simon's 2-stage, phase II study of paclitaxel and
      cisplatin as neoadjuvant therapy in patients with FIGO IB2 or IIA2, squamous cell cervical
      carcinoma of the uterine cervix.

      Primary Objectives:

      • Overall survival

      Secondary Objectives:

        -  Safety

        -  Progression-free survival

        -  Response rate

        -  Postoperative RT/CRT rate

        -  To assess Quality-of-life

      An estimate of 64 evaluable patients will be enrolled in this phase II investigation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survivial</measure>
    <time_frame>January 31, 2023 (5 years)</time_frame>
    <description>The primary objective is to determinate the difference in 5-year survival rate of subjects with NAC+RH-PLND compared with standard CCRT. Based on the pilot research, the 5-year survival rate of NAC+RH-PLND is expected to be around 87.5%. Thus, a sample size of 64 subjects in NAC+RH-PLND group is required for correctly detecting a 12.5% difference between 5-year OS rate of NAC+RH-PLND group and a reference value 75% of standard CCRT in order to achieving an 80% power at a significance level 0.05.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (If &gt; 6 significant G3/4 AEs occur)</measure>
    <time_frame>January 31, 2023 (up to 5 years)</time_frame>
    <description>If &gt; 6 significant G3/4 AEs occur</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (Pathological response)</measure>
    <time_frame>Post-operative 1 month</time_frame>
    <description>Pathological response will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative RT/CRT rate</measure>
    <time_frame>Post-operative 6 months</time_frame>
    <description>Postoperative RT/CCRT will be given to defined high-risk group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life</measure>
    <time_frame>at completion of neoadjuvant chemotherapy</time_frame>
    <description>using EORTC QLQ-C30, EORTC-QLQ-CX24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>January 31, 2023 (up to 5 years)</time_frame>
    <description>PFS will be evaluated using Kaplan-Meier method</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Weekly paclitaxel and cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7-day cycle schedule of paclitaxel (60 mg/m2) combining with cisplatin (40 mg/m2) NAC regimen followed by radical hysterectomy and bilateral pelvic lymphadenectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>7-day cycle schedule of paclitaxel (60 mg/m2)</description>
    <arm_group_label>Weekly paclitaxel and cisplatin</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>7-day cycle schedule of cisplatin (40 mg/m2)</description>
    <arm_group_label>Weekly paclitaxel and cisplatin</arm_group_label>
    <other_name>Kemoplat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical hysterectomy and bilateral pelvic lymphadenectomy</intervention_name>
    <description>2 weeks after last course of neoadjuvant chemotherapy</description>
    <arm_group_label>Weekly paclitaxel and cisplatin</arm_group_label>
    <other_name>RH-PLND</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women with previously untreated, histologically confirmed squamous cell carcinoma of
             the uterine cervix

          2. HPV16-positive aged 35-70 years or HPV16-negative age &lt;55 years

          3. FIGO stage IB2 or bulky IIA, with tumor extending to the vagina within the upper one
             third of the vaginal wall. Bulky tumor is defined as

               1. a visible cervical tumor with the largest diameter &gt;4 cm or (b) a cervix expanded
                  to &gt; 4 cm as a result of tumor infiltration by pelvic examination

               2. verified by magnetic resonance image (MRI) or 3-dimensional (D) computed
                  tomography (CT)

          4. no suspicious extrapelvic metastasis detected by MRI or 3-D CT

          5. adequate marrow, liver and renal functions :hemoglobin level &gt;= 10 g/dL, WBC count &gt;=
             3,000/mm3 or absolute neutrophil count &gt;= 1,500/mm3, platelet count &gt;= 100,000/mm3,
             serum transaminase (AST, ALT) levels &lt;= 60 IU/mL, total serum bilirubin within normal
             range, serum creatinine level &lt;= 1.5 mg/dL, and blood urea nitrogen level &lt;=20 mg/dL

          6. adequate cardiopulmonary function that tolerates the administration of study regimen
             and radical hysterectomy

          7. Eastern Cooperative Oncology Group performance status of 0 to 1

          8. had written informed consent to participate in the study

          9. Appropriate organ and marrow function :

             leukocytes &gt;=3,000/μL absolute neutrophil count &gt;= 1,500/μL platelets &gt;= 100,000/μL
             (not platelet transfusion dependent) hemoglobin &gt;= 10 g/dL total bilirubin within
             normal range AST/ALT &lt;= 2.5 X upper limit of normal range (ULN) BUN &lt;= 20 mg/dL serum
             creatinine &lt;=1.5 mg/dL or clearance &gt; 60 mL/min

         10. a negative urinary pregnancy test in a patient with child-bearing potential

        Exclusion Criteria:

        Patients will be excluded from the study if they meet any of the following criteria:

          1. adenocarcinoma , adenosquamous carcinoma, or small cell carcinoma

          2. concurrent or history of malignant tumor(s) other than treated nonmelanoma skin cancer

          3. had received surgical procedure other than cervical biopsy or cytotoxic procedure
             including chemotherapy, radiotherapy or therapy with biologic response modifier(s) for
             the cervical tumor

          4. enlarged pelvic lymph node with positive aspiration cytologic or histologic study

          5. participate in investigational treatment or another clinical trial for cervical cancer

          6. history of allergic reaction to platinum or paclitaxel

          7. uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          8. pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huei-Jean Huang, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huei-Jean Huang, M.D</last_name>
    <phone>03-3281200</phone>
    <phone_ext>8984</phone_ext>
    <email>hjhuang@cgmh.org.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics &amp; Gynecology, Chang Gung Memorial Hospital</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chih-Wen Tseng, M.D.</last_name>
      <email>otcwwell@cgmh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Chih-Wen Tseng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics &amp; Gynecology, Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hung-Chun Fu, M.D.</last_name>
      <phone>886-7-731-7123</phone>
      <phone_ext>8916</phone_ext>
      <email>allen133@adm.cgmh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Hong-Jun Fu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chih-Jen Tseng, M.D.</last_name>
      <phone>886-4-24739595</phone>
      <phone_ext>34121</phone_ext>
      <email>obgyntw@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chih-Jen Tseng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics &amp; Gynecology, Chang Gung Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jui-Der Liou, M.D.</last_name>
      <phone>886-2-27135211</phone>
      <phone_ext>3345</phone_ext>
      <email>liou88@ms13.hinet.net</email>
    </contact>
    <investigator>
      <last_name>Jui-Der Liou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Gynecologic Oncology, Department of Obstetrics &amp; Gynecology, Chang Gung Memorial Hospital Linkou Medical Center</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huei-Jean Huang, M.D.</last_name>
      <email>hueijean.huang@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Huei-Jean Huang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://medlineplus.gov/hysterectomy.html</url>
    <description>MedlinePlus related topics</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/name/Cisplatin</url>
    <description>Drug Information available for: Cisplatin</description>
  </link>
  <link>
    <url>https://druginfo.nlm.nih.gov/drugportal/name/Paclitaxel</url>
    <description>Drug Information available for: Paclitaxel</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>U.S. FDA Resources</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>May 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2015</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Huei-Jean Huang</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Paclitaxel</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Cervical cancer</keyword>
  <keyword>Radical hysterectomy</keyword>
  <keyword>Neoadjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

